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Influenza virus (IFV) is a major respiratory pathogen of global importance, and the cause 
of a high degree of morbidity and mortality, especially in high-risk populations such as 
infants, elderly, and immunocompromised hosts. Given its high capacity to change 
antigenically, acquired immunity is often not effective to limit IFV infection and therefore 
vaccination must be constantly redesigned to achieve effective protection. Improvement 
of respiratory and systemic innate immune mechanisms has been proposed to reduce 
the incidence and severity of IFV disease. In the last decade, several research works 
have demonstrated that microbes with the capacity to modulate the mucosal immune 
system (immunobiotics) are a potential alternative to beneficially modulate the outcome 
of IFV infection. This review provides an update of the current status on the modulation 
of respiratory immunity by orally and nasally administered immunobiotics, and their 
beneficial impact on IFV clearance and inflammatory-mediated lung tissue damage. 
In particular, we describe the research of our group that investigated the influence of 
immunobiotics on inflammation–coagulation interactions during IFV infection. Studies 
have clearly demonstrated that hostile inflammation is accompanied by dysfunctional 
coagulation in respiratory IFV disease, and our investigations have proved that some 
immunobiotic strains are able to reduce viral disease severity through their capacity to 
modulate the immune-coagulative responses in the respiratory tract.
Keywords: immunobiotics, influenza virus, inflammation, coagulation, respiratory immunity
iNTRODUCTiON
Influenza virus (IFV) is a member of the Orthomyxoviridae family that contains a negative-sense, 
single-stranded, segmented RNA genome protected by a capsid of viral ribonucleoproteins. This 
virus is categorized into subtypes based on the expression of hemagglutinin (HA) and neuramini-
dase on the surface of the viral envelope.
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Influenza is a highly contagious viral infection that has a sub-
stantial impact on global health and IFV is a major respiratory 
pathogen that causes a high degree of morbidity and mortality, 
especially in high-risk populations such as infants, elderly, and 
immunocompromised hosts. Given the high capacity of IFV to 
change antigenically, acquired immunity is often not effective 
to limit infection and therefore vaccination must be constantly 
redesigned to achieve protection. Improvement of respiratory 
and systemic innate immune mechanisms has been proposed to 
reduce the incidence and severity of IFV disease.
In the last decade, several research works have demonstrated 
that microbes with the capacity to modulate the mucosal immune 
system (immunobiotics) are a potential alternative to beneficially 
modulate the outcome of IFV infection. This review provides an 
update of the current status on the modulation of respiratory 
immunity by orally and nasally administered immunobiotics, 
and their beneficial impact on IFV clearance and inflammatory-
mediated lung tissue damage. In particular, we describe the 
research of our group that investigated the influence of immu-
nobiotics on inflammation–coagulation interactions during 
IFV infection. Studies have clearly demonstrated that hostile 
inflammation is accompanied by dysfunctional coagulation in 
respiratory IFV disease, and our investigations have proved that 
some immunobiotic strains are able to reduce viral disease sever-
ity through their capacity to modulate the immune-coagulative 
responses in the respiratory tract.
ReSPiRATORY iMMUNe ReSPONSe  
AND iFv
The first barrier that protects the host against IFV infection is 
the respiratory epithelium through its capacity to recognize the 
viral attack. When IFV successfully overcomes the respiratory 
barrier constituted by the mucus layer and the ciliar movement, 
it mediates its attachment and internalization into respiratory 
epithelial cells to start its replication (1). During the viral attack, 
several pathogen-associated molecular patterns (PAMPs) are 
exposed and recognized by pattern-recognition receptors (PRRs) 
expressed in respiratory cells (Figure  1). It is now well estab-
lished that the most important PRRs involved in the recognition 
of IFV are the Toll-like receptor (TLR)-3 and TLR7 and the RNA 
recognition protein RIG-1 (2). TLR3 is expressed in endosomes 
and is able to recognize viral double-stranded RNA (dsRNA) 
that is produced during viral replication; while endosomal TLR7 
and cytoplasmic RIG-I recognize single-stranded RNA (ssRNA). 
RIG-I signals through mitochondrial antiviral signaling protein. 
The PAMPs–PPRs interaction leads to the activation of several 
signaling pathways that induce the activation of nuclear factor 
κB (NF-κB) and interferon (IFN) regulatory factor 3 (IRF3) 
and the production of type I and III IFNs and inflammatory 
cytokines (2).
Type I IFNs, especially IFN-β, produced and released during 
the earlier stages of IFV infection are key to develop an anti-
viral state in the respiratory tract. It was reported that human 
bronchial epithelial cells release preformed IFN-β in response to 
IFV challenge inducing a protective role (3). IFNs produced by 
infected cells are able to act in a paracrine or autocrine manner 
activating their receptors (IFNAR) and increasing the expression 
of hundreds of genes that counteract viral replication. Functional 
genomic studies have identified several of the IFN-induced 
factors that have important roles in controlling IFV replication 
(2) including the IFN-inducible transmembrane proteins 1, 2, 
and 3 (4), MX1 proteins (5), and 2′,5′-oligoadenylate synthetase 
(OAS)-RNAaseL system (6).
Proinflammatory cytokines and chemokines produced as a 
result of TLR3 and RIG-I activation during IFV infection are 
also important for the generation of the respiratory antiviral 
innate immune response. Infection of epithelial cells by IFV 
increases the expression of TNF-α, IL-6, IL-8, CCL2 (MIP-1), 
CCL5 (RANTES), CCL3 (MIP-1α), and CXCL10 (IP-10) (7). 
The production of these cytokines is complemented by activity 
of inflammasomes that induce the activation of caspase-1 and 
promote the generation of the active forms of IL-1β and IL-18 
(Figure 1). IFV has been shown to activate mainly the NLRP3 
inflammasome which is essential for the protection against 
the virus since several studies demonstrated that mice lacking 
NLRP3 or caspase-1 have decreased IL-1β and IL-18 secretion 
and increased mortality after IFV challenge (8–10).
The proinflammatory cytokines and chemokines are 
responsible for the activation of resident immune cells such 
as innate lymphoid cells, alveolar macrophages, and dendritic 
cells (DCs) as well as for the recruitment of neutrophils, 
macrophages, and lymphocytes into the respiratory tract (2, 7) 
(Figure 2). Respiratory cells infected with IFV express HA on 
their surface that is important for its recognition by NK cells 
(11). It was established that HA expressed by the infected cells 
is recognized by NKp44 and PKp46 receptors of NK cells that 
then mediated the lysis of IFV-infected cells (12). Macrophages 
activated during IFV infection produce IFNs, IL-6, TNF-α, and 
nitric oxide synthase that amplify the inflammatory response. In 
addition, macrophages limit the viral spread by the elimination 
of apoptotic-infected cells and through phagocyte-mediated 
opsonophagocytosis of IFV (7). The production of proinflam-
matory cytokines during the generation of the respiratory innate 
immune response against IFV also conditions the adaptive 
immune response, which includes the production of virus-
specific systemic and mucosal antibodies as well as the induction 
of specific T cell responses (13).
After exposure to IFV there is an activation of antibody 
responses in the respiratory tract. Upper airway exposure results 
primarily in an IgA response while the contact of IFV with the 
deep lung induces an increased production of pathogen-specific 
IgG (14). Following exposure to IFV in the airways there is 
an antigen uptake and processing by DCs, activation of CD4+ 
Th  cells, and  generation of IgA-producing plasma cells that 
populate airway lamina propria. Secretory IgA has a non-
inflammatory protective function since these antibodies can 
bind to virus without activating complement or stimulating 
the release of inflammatory mediators by innate immune cells 
(14, 15). IgA prevents IFV from adhering to the epithelial surface 
by inducing viral agglutination, and masking adhesion epitopes. 
In the deep lung, when IFV reach the alveolar space, there is 
a differentiation and expansion of antibody-secreting plasma 
cells that are committed to the production of IgG. Induction of 
FigURe 1 | Signaling pathways activated by the recognition of influenza virus-associated molecular patterns by pattern-recognition receptors 
expressed in respiratory epithelial cells and immune cells.
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neutralizing respiratory and serum IgG antibodies is a key event 
in the defense against influenza infection since IgG prevents 
systemic spread (16). Influenza infection in the lungs also acti-
vates the cellular adaptive immune response by stimulating the 
production of IFN-γ by Th1 cells that effectively activate CD8+ 
T cells and macrophages, which clear virus and infected cells 
from the lungs (17). Therefore, during uncomplicated influenza, 
adaptive immune response ultimately results in clearance of IFV 
from the lungs through the activity of virus-specific antibodies 
and CD4+ and CD8+ T cells.
ROLe OF MiCROBiOTA ON iFv 
iNFeCTiON
The gut microbiome, which is defined as the collective group of 
microorganisms and their associated genes within the intestinal 
tract, is considered as a key player in the modulation of host 
intestinal immune responses (18, 19). In fact, the impact of 
gut commensal bacteria on the innate and adaptive immune 
responses to enteric pathogens has been recognized conclusively 
(20–22). However, the effect of gut microbiome on the immune 
FigURe 2 | innate immune response against influenza virus in the respiratory mucosa mediated by the recognition of viral-associated molecular 
patterns by pattern-recognition receptors expressed in respiratory epithelial cells. Beneficial effects of immunobiotics administration on the resistance and 
immune response against Influenza Virus in the respiratory mucosa.
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responses in distal mucosal sites and its impact in the outcome of 
respiratory infections has recently been exposed. In this regard, 
some studies have demonstrated an important role for intestinal 
microbiota in maintaining respiratory antiviral immunity against 
IFV (23, 24).
Iwasaki and colleagues observed that commensal bacteria 
within the gut, especially gram-positive bacterial populations, 
had an important role in supporting an appropriate immune 
response to IFV infection in the respiratory tract (23). The 
work demonstrated that oral antibiotic treatments impaired the 
resistance of mice to the intranasal infection with IFV as noted 
by the elevated lung viral titers when compared to non-antibiotic-
treated animals. Results indicated that gut gram-positive bacteria 
provided protection by triggering an adequate inflammatory 
response through inflammasomes activation. In antibiotic-
treated mice, synthesis of pro-IL-1β, pro-IL-18, and NLRP3 was 
impaired even at the steady state. In addition, depletion of gram-
positive bacterial populations in the gut resulted in an alteration 
of the distribution and activation of respiratory DCs at steady 
state as well as in a diminished DCs migration from the lung 
to the draining lymph nodes, resulting in reduced activation of 
CD8+ and CD4+ T cells after influenza challenge (23). Alteration 
of respiratory DCs activities also correlated with impaired expan-
sion of influenza-specific B cells and reduced influenza-specific 
antibodies.
By using germ-free and antibiotic-treated mice challenged 
with IFV, Abt et al. (24) showed that the absence or the alteration 
of intestinal microbiota induced an exacerbated weight loss, a 
greater drop in blood oxygen saturation, increased mortality, and 
elevated lung viral titers indicating a weaker ability to resist influ-
enza. Even more, germ-free and antibiotic-treated mice infected 
with IFV experienced higher epithelial cell necrosis, peribronchi-
olar inflammation, severe bronchiole epithelial degeneration, and 
epithelial hyperplasia when compared to conventional animals 
(24). Interestingly, those effects were observed when both the 
PR8 strain and the X31-GP33 virus, a less pathogenic strain of 
IFV that causes minimal mortality and morbidity in conventional 
mice, were used. Consistent with the work by Ichinohe et al. (23), 
germ-free and antibiotic-treated mice challenged with IFV had 
an impaired adaptive immune response as shown by the lower 
influenza-specific antibodies (serum IgM and IgG), fewer num-
ber of IFV-specific T cells present in lungs, as well as a reduced 
capacity of specific T cells to produce effector cytokines such 
as TNF-α, MIP-1α, IL-2, and IFN-γ (24). Moreover, authors 
demonstrated that the alterations of adaptive immune responses 
were related to defects in the early innate immune response 
mediated by macrophages. In fact, transcriptional profiling and 
computational analyses of macrophages from antibiotic-treated 
mice indicated a reduced expression of antiviral genes includ-
ing Ifnb, Tnfa, Il1b, Irf7, Mx1, and Oas1a when compared to 
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conventional mice. In addition, functional assays of macrophages 
from antibiotic-treated mice demonstrated that those cells had 
a defective response to type I IFNs and an impaired capacity to 
limit IFV replication (24).
The cellular and molecular mechanisms through which 
the gut microbiome and their derived signals maintain and 
modulate immune responses in distal mucosal sites are poorly 
understood. Two possible mechanisms that are not mutually 
exclusive have been proposed to explain this beneficial effect 
of the gut microbiome. One possibility is that distal mucosal 
and peripheral immune cells are directly exposed to bacterial 
products that activate PRRs in the steady state and help to main-
tain the normal immune tone. There is evidence that bacterial 
products from gut commensals such as peptidoglycan can be 
absorbed and circulate throughout the host and help to modu-
late the normal development of immune cells (25). In line with 
this hypothesis, Iwasaki and colleagues speculated that bacte-
rial products from gut commensals trigger PRRs to stimulate 
immune cells systemically and that factors released by those cells 
supported steady-state production of pro-IL-1β, pro-IL-18, and 
NLR proteins. This idea was sustained by their observation that 
intestinal injection of TLR ligands restored immune responses 
to IFV in antibiotic-treated mice (23). Another possibility is that 
commensal bacteria may indirectly influence systemic and distal 
mucosal immune responses through immune factors released 
from the intestinal mucosa including cytokines, chemokines, 
and grow factors.
These research works demonstrated that the gut microbiome 
provides signals to sustain antiviral innate immune defense 
mechanisms in the respiratory tract allowing robust and efficient 
effector responses upon challenge by viral pathogens such as IFV. 
Therefore, the role of the gut microbiome in regulating respira-
tory antiviral immunity represents an exciting area of research 
that could help to provide the scientific basis for the develop-
ment of novel prevention strategies for lung infectious diseases. 
However, several questions need to be answered to identify 
new alternatives to improve antiviral respiratory defenses by 
modulating the microbiota. How the different microbial species 
from the gut microbiota influence the common mucosal immune 
system? Which PRRs are activated by the gut microbiota to 
functionally modulate antiviral immunity locally and in distal 
mucosal sites? Which cellular functions are modulated by the 
microbiota after PRR activation? Has the microbiota the ability 
to influence immune responses to other respiratory viruses? 
Are similar immune mechanisms activated by the microbiota 
in high-risk populations (infants, elderly, immunocompromised 
hosts) in which respiratory viral infections are more frequent and 
severe? Is it possible to beneficially modulate antiviral respiratory 
defenses by orally administering selected microorganisms with 
immunomodulatory capacities? Research from the last years has 
provided some answers for the last question.
BeNeFiCiAL eFFeCTS OF 
iMMUNOBiOTiCS ON iFv iNFeCTiON
The first studies that assessed the capacity of immunobiotics to 
favorably modulate the immune response against IFV focused 
on the humoral immunity (Table 1). Yasui et al. (26) reported 
that the oral administration of Bifidobacterium breve YIT4064 
improved the production of anti-IFV IgG antibodies in serum 
of IFV-infected mice. The YIT4064 strain reduced viral titers, 
improved the survival rate, and decreased the severity of the 
symptoms associated to the influenza infection. Similarly, it 
was shown that orally administered non-viable Lactobacillus 
pentosus b240 (27) or viable Lactobacillus brevis KB290 (28) 
were able to improve the levels of respiratory specific IgA and 
IgG antibodies of mice challenged with IFV. Moreover, the 
improved humoral response induced by these strains correlated 
with significant reduction of viral titers, body weight loss, and 
a decrease of the alterations of physical conditions induced by 
IFV. More recently, Kikuchi et al. (29) demonstrated a beneficial 
effect on the outcome to IFV infection related to an improved 
respiratory humoral response in Lactobacillus plantarum AYA-
treated mice. In addition, the work proposed a mechanism 
for the distal immunomodulatory activity induced by orally 
administered immunobiotics. Authors showed that L. plantarum 
AYA fed to mice impacted in Peyer’s patches (PPs) inducing an 
activation of antigen presenting cells (mainly CD11b+ DCs) and 
increasing the production of IL-6. Those changes promoted an 
IgM-to-IgA class switch recombination, the differentiation of 
IgA+ B cells into plasma cells, and improved the production 
of mucosal IgA in both the intestine and the respiratory tract. 
Those studies show that immunobiotics are capable to modulate 
the production of systemic and mucosal antibodies against 
influenza and therefore, to enhance the humoral immune 
response (Figure 2). However, the precise mechanism by which 
orally administered immunobiotics induce IgA production in 
distant mucosal sites remains unclear.
It was also demonstrated that immunobiotics are able to 
improve cellular immune response against IFV (Figure  2). In 
this regard, it was reported that orally administered Lactobacillus 
casei Shirota improved the outcomes of IFV infection of aged (30) 
and infant mice (31) by increasing systemic and respiratory NK 
cell activity and improving the production of IFN-γ and TNF-α 
by respiratory lymphocytes. Both studies also demonstrated that 
IFV titers were significantly reduced in aged and infant mice 
treated with the Shirota strain (30, 31). Similar to the mechanism 
proposed to explain the improvement of humoral response, it 
was postulated that immunobiotic L. casei Shirota stimulated Th1 
cells and NK cells in PPs and induced a mobilization of those cells 
to lungs and respiratory-associated lymphoid tissues where they 
produced IFN-γ and enhanced the antiviral defenses. Several 
other studies corroborated these findings by showing similar 
effects for orally administered lactobacilli (32, 33). Immunobiotic 
Lactobacillus strains (L. gasseri TMC0356, L. rhamnosus GG, or L. 
plantarum 06CC2) beneficially modulated NK cells activity and 
Th1 response against IFV, diminished virus titers and reduced 
lung pathological changes (32, 33) (Table  1). More recently, 
Kawahara et  al. (34) described the improvement of respiratory 
antiviral response by an orally administered bifidobacteria strain. 
It was shown that Bifidobacterium longum MM-2 increased 
respiratory NK cell activity and IFN-γ production resulting in 
improved clinical symptoms, reduced mortality, and decreased 
virus titers after IFV challenge.
TABLe 1 | effect of immunobiotics on influenza virus (iFv) infection in mice models.
immunobiotic 
strain
viability Administration protocol Challenge Mice immunobiotic effects effect on iFv infection Reference
effects on humoral immune response
Bifidobacterium 
breve YIT4064
Non-viable Oral ad libitum administration of food with 
0.05% B. breve YIT4064 during 15 weeks 
before IFV challenge. Treatment was 
continued for 2 weeks after infection
IFV (H1N1) 
strain  
A/PR/8/34
Six-week-old 
male BALB/c
Improved the production of anti-IFV IgG 
antibodies in serum
Reduced viral titers, improved 
survival rate, and decreased 
severity of symptoms
(26)
Lactobacillus 
pentosus b240
Non-viable L. pentosus was administered by gavage 
at doses of 0.4, 2, or 10 mg per mouse per 
day during 21 days before IFV challenge. 
Treatment was continued for 2 weeks after 
infection
IFV (H1N1) 
strain  
A/PR/8/34
Six-week-old 
female BALB/c
Improved levels of respiratory IgA and 
IgG specific antibodies
Reduced IFV titers (27)
Lactobacillus brevis 
KB290
Viable L. brevis was administered by gavage at a 
dose of 109 cells per mouse per day during 
14 days before IFV challenge
IFV (H1N1) 
strain  
A/PR/8/34
Six to eight-
week-old female 
BALB/c
Improved levels of IFV-specific IgA in the 
respiratory tract
Reduced body weight loss 
and decreased alterations of 
physical conditions
(28)
Lactobacillus 
plantarum AYA
Non-viable Oral ad libitum administration of food with 5% 
of L. plantarum AYA (120 mg per mouse per 
day) during 28 days before IFV challenge
IFV (H3N2) 
strain X-31
Seven-week-old 
female BALB/c
Improved the production of IgA in the 
respiratory tract
Reduced body weight loss and 
decreased mortality
(29)
effects on cellular immune response
Lactobacillus casei 
Shirota
Non-viable Oral ad libitum administration of food with 
0.05% of L. casei Shirota during 4 weeks 
before IFV challenge
IFV (H1N1) 
strain  
A/PR/8/34
Fifteen-week-old 
female BALB/c
Improved systemic and respiratory 
NK cell activity and production of 
interferon (IFN)-γ and TNF-α by 
respiratory lymphocytes
Reduced IFV titers (30)
L. casei Shirota Viable L. casei Shirota was administered by gavage 
at a dose of 109 cells per mouse 5 times/
week for about 3 weeks (total, 17 times) 
before IFV challenge
IFV (H1N1) 
strain  
A/PR/8/34
Neonatal and 
infant mice
Improved systemic and respiratory 
NK cell activity and production of IFN-γ 
and TNF-α by respiratory lymphocytes
Reduced IFV titers, decreased 
accumulated symptom rate, 
and decreased mortality
(31)
Lactobacillus 
gasseri TMC0356
Viable Ten milligrams of lyophilized bacteria in 
200 µl of saline was administered orally per 
day during 14 days before IFV challenge. 
Treatment was continued for 5 days after 
infection
IFV (H1N1) 
strain  
A/PR/8/34
Five-week-old 
female BALB/c
Improved NK cell activity and 
production of IFN-γ
Reduced virus titers and 
diminished lung pathological 
changes
(32)
Lactobacillus 
rhamnosus GG
Viable Ten milligrams of lyophilized bacteria in 
200 µl of saline was administered orally per 
day during 14 days before IFV challenge. 
Treatment was continued for 5 days after 
infection
IFV (H1N1) 
strain  
A/PR/8/34
Five-week-old 
female BALB/c
Improved NK cell activity and 
production of IFN-γ
Reduced virus titers and 
diminished lung pathological 
changes
(32)
L. plantarum 
06CC2
Non-viable L. plantarum was administered by gavage 
twice daily during 2 days before IFV challenge 
(20 mg/mouse). Treatment was continued for 
7 days after infection
IFV (H1N1) 
strain  
A/PR/8/34
Six-week-old 
female BALB/c
Beneficially modulated NK cells activity 
and improved Th1 response
Reduced virus titers and 
diminished lung pathological 
changes
(33)
(Continued )
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immunobiotic 
strain
viability Administration protocol Challenge Mice immunobiotic effects effect on iFv infection Reference
Bifidobacterium 
longum MM-2
Viable Oral administration of 2 × 109 cells per mouse 
per day during 14 days before IFV challenge. 
Treatment was continued for 2 days after 
infection
IFV (H1N1) 
strain  
A/PR/8/34
Six-week-old 
female BALB/c
Increased respiratory NK cell activity 
and IFN-γ production
Improved clinical  
symptoms, reduced 
mortality, and decreased 
virus titers
(34)
L. casei Shirota Non-viable Nasal administration of 20 or 200 µg per 
mouse per day during 3 days before IFV 
challenge
IFV (H1N1) 
strain  
A/PR/8/34
Ten to eleven-
week-old female 
BALB/c
Increased levels of IL-12, IFN-γ, and 
TNF-α in mediastinal lymphoid nodes 
and lungs
Decreased virus titers and 
increased survival rates
(35)
L. pentosus S-PT84 Non-viable Nasal administration of 20 or 200 µg per 
mouse per day during 3 days before IFV 
challenge
IFV (H1N1) 
strain  
A/PR/8/34
Eight to twelve-
week-old female 
BALB/c
Increased IL-12, IFN-α, and NK cell 
activity in the respiratory tract. Increased 
levels of IL-12 and IFN-γ in mediastinal 
lymphoid nodes
Decreased virus titers and 
increased survival rates
(36)
L. rhamnosus GG Viable Nasal administration of 200 µg per mouse per 
day during 3 days before IFV challenge
IFV (H1N1) 
strain  
A/PR/8/34
Seven-week-old 
female BALB/c
Increased respiratory NK cell activity Reduced IFV titers, decreased 
accumulated symptom rate, 
and increased survival rates
(37)
L. rhamnosus Viable Sublingual administration of 108 cells per 
mouse per day during 7 days before IFV 
challenge
IFV (H1N1) 
strain  
A/FMI/33
Adult female 
BALB/c
Improved levels of IgA specific 
antibodies, IL-12, and decreased levels 
of TNF-α and IL-6 in lungs. Increased 
NK cell activity in spleen. Increased 
CD25 expression by CD4+ and CD8+ in 
lung and mediastinal lymphoid nodes
Increase of the survival rates 
and decrease in the lung lesion 
scores
(38)
effects on innate immune response
L. plantarum L-137 Non-viable Intragastric administration of 5–100 mg/
kg of mouse per day during 7 days before 
IFV challenge. Treatment was continued for 
7 days after infection
IFV (H1N1) 
strain  
A/NWS/47
Seven-week-old 
female C57BL/6
Improved production of type I IFNs Reduced viral loads in lungs 
and improved survival
(39)
L. gasseri SBT2055 Viable Oral administration of 108 or 109 cells per 
mouse per day during 7–21 days before IFV 
challenge
IFV (H1N1) 
strain  
A/PR/8/34
Five to seven-
week-old male 
C57BL/6
Enhanced lung expression of the 
antiviral genes Mx1 and Oas1a and 
differentially regulated inflammatory 
response
Enhanced survival rates, 
reduced lung viral titers and 
diminished lung inflammatory 
damage
(40)
L. rhamnosus 
CRL1505
Viable Oral administration of 108 cells per mouse per 
day during 5 days before IFV challenge
IFV (H1N1) 
strain  
A/PR/8/34
Six-week-old male 
BALB/c
Differentially regulated levels and kinetics 
of inflammatory cells (neutrophils and 
macrophages) and cytokines (TNF-α, 
IL-6, IL-10, and type I IFNs)
Diminished coagulation activation in 
blood and respiratory tract
Decreased IFV titers in lungs, 
lessened pulmonary damage, 
and increased survival
(41)
L. rhamnosus 
CRL1505
Viable and 
non-viable
Nasal administration of 108 cells per mouse 
per day during 2 days before IFV challenge
IFV (H1N1) 
strain  
A/PR/8/34
Six-week-old male 
BALB/c
Differentially regulated levels and kinetics 
of inflammatory cells (neutrophils and 
macrophages) and cytokines (TNF-α, 
IL-6, IL-10, and type I IFNs)
Diminished coagulation activation in 
blood and respiratory tract
Decreased IFV titers in lungs, 
lessened pulmonary damage, 
and increased survival
(42)
(Continued )
TABLe 1 | Continued
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Research work has also demonstrated that nasal administra-
tion of immunobiotics is an interesting alternative to improve 
cellular response against influenza infection (35–37) (Table 1). 
Hori et al. (35) observed that BALB/c mice nasally treated with 
non-viable L. casei Shirota had increased levels of IL-12, IFN-
γ, and TNF-α in mediastinal lymphoid nodes and lungs. This 
improved cellular respiratory immunity correlated with a benefi-
cial clinical outcome to IFV challenge. Similar observations were 
performed with nasally administered L. pentosus S-PT84 (36) and 
L. rhamnosus GG (37).
Other recent studies have also demonstrated the ability of 
immunobiotics to improve respiratory innate antiviral defenses 
in the respiratory tract (Table 1; Figure 2). It was reported that 
orally administered non-viable L. plantarum L-137 improved 
protection against IFV by increasing type I IFN production (39). 
The work clearly demonstrated that the increased production of 
IFN-β induced by the immunobiotic strain correlated with the 
reduction of viral loads in lungs as well as the improved survival 
of infected mice. More recently, it was shown that L. gasseri 
SBT2055 enhanced survival rates and reduced lung viral titers in 
mice infected with IFV (40). Interestingly, authors observed that 
the lung expression of the antiviral genes Mx1 and Oas1a was 
enhanced in L. gasseri SBT2055-treated mice and that the inflam-
matory response triggered by IFV was differentially regulated 
inducing a lower inflammatory damage (40).
Our group has also reported a beneficial regulation of the 
IFV-triggered inflammatory response by immunobiotics. Lung 
damage induced by IFV is known to be produced by virus 
replication as well as the uncontrolled inflammatory response 
that is characterized by a hypersecretion of proinflammatory 
cytokines, especially TNF-α, IL-1β, and IL-6 (45). The adequate 
production of inflammatory factors is necessary to protect 
against IFV infection together with an appropriate regulation 
with anti-inflammatory cytokines to prevent the damage of lung 
tissue. Thus, the proper balance of cytokines is a key factor in 
determining the outcome of IFV infection. In this regard, we 
observed that orally (41) or nasally (42) administered immu-
nobiotic L. rhamnosus CRL1505 differentially regulated the 
levels and kinetics of inflammatory cells and cytokines in mice 
after IFV challenge. In our experimental model, we observed 
increased levels of respiratory TNF-α, IL-6, neutrophils, and 
macrophages in CRL1505-treated mice early after the challenge 
with IFV. Later, proinflammatory cytokines and infiltrated cells 
started to decrease in immunobiotic-treated animals in contrast 
to control mice, in which those parameters continued increasing. 
The trend toward lower inflammatory factors and cells registered 
later during IFV infection in L. rhamnosus CRL1505-treated mice 
correlated with a reduced severity of pulmonary damage when 
compared to control mice (41, 42).
Chen et al. (43) also investigated the ability of orally admin-
istered Enterococcus faecalis KH2 to beneficially modulate 
the innate immune response to influenza infection. Authors 
observed that KH2 strain protected C57BL/6 mice against IFV 
as observed by the reduced mortality, weight loss, and lung viral 
titers. As expected, IFV enhanced the levels of proinflammatory 
mediators in the respiratory tract including IL-6, TNF-α, IFN-γ, 
IL-1β, IL-17, and MCP-1 while the treatment with E. faecalis 
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significantly diminished the concentrations of proinflammatory 
factors, especially MCP-1. Considering that monocyte migration 
mediated by MCP-1 has been linked to several respiratory inflam-
matory disorders including IFV infection, authors investigated 
the role of MCP-1/CCR2 pathway in the immunobiotic effect of 
E. faecalis KH2. The work reported that the protective activity 
of the KH2 strain was abrogated when recombinant MCP-1 was 
administered concomitantly (43).
It is not clear how immunobiotics initiates the cross-talk 
with the immune system in order to modulate the respiratory 
antiviral immunity. It is not known exactly which PRRs are 
activated by immunobiotics in the intestinal or respiratory 
mucosa to functionally modulate antiviral immunity locally 
and in distal mucosal sites, respectively. Neither it has been 
determined with exactitude which cellular functions are 
modulated by immunobiotics immediately after PRR activa-
tion. Research from the last decade has demonstrated that 
the immunomodulatory effects of probiotic bacteria are the 
consequence of complex interactions between several bacterial 
molecules and host receptors located in different immune and 
non-immune cells (46, 47). It has also been shown that the 
immunomodulatory properties of immunobiotics are depend-
ent on the strains. Therefore, studies carried out with certain 
strains cannot be easily extrapolated to other bacteria, even 
those of the same genus and species (48, 49). Consequently, 
it is still necessary to carry out deeper studies to find out the 
molecular mechanisms by which immunobiotics beneficially 
influence the respiratory antiviral immunity.
The studies mentioned before showed the potential of 
immunobiotics to be used for the reduction of the incidence and 
severity of IFV infections. However, in addition to deepening the 
knowledge of their mechanisms of action, several other points 
should be considered for the efficient application of immunobiot-
ics in humans.
For example, it is necessary to determine the best time as 
well as the most appropriate route for their administration. 
Immunobiotics used as components of functional foods can be 
included in diets on a regular basis and thus help to improve 
respiratory defenses, especially in high-risk populations and 
during the seasons with the highest incidence of respiratory 
infections occurs. In this sense, in a randomized controlled trial 
we demonstrated that L. rhamnosus CRL1505 (administered in a 
yogurt formulation) improved mucosal immunity and reduced 
the incidence and severity of intestinal and respiratory infection 
in children (50). Hence, the incidence of infectious events was 
reduced from 66% in the placebo group to 34% in the group 
that received the probiotic yogurt. Furthermore, there was also 
a significant reduction in the occurrence of indicators of disease 
severity such as fever and the need for antibiotic treatment in 
children receiving the probiotic yogurt. This immunobiotic 
yogurt (YOGURITO®) has been included into official National 
Nutritional Programs in Argentina and is given daily to chil-
dren at schools in several provinces thanks to the Government 
actions. Epidemiological studies in the schools receiving the 
immunobiotic product have shown a reduction in the incidence 
of infections and in the associated school absenteeism (Alvarez 
et al., unpublished results).
On the other hand, as mentioned earlier the nasal admin-
istration of immunobiotics is more efficient than the oral 
administration to enhance respiratory immunity. This route of 
administration poses a practical disadvantage considering that 
the treatments with immunobiotics showed favorable results 
when they were used before the infectious challenges. In this 
way, it would be necessary to predict the exact moment in which 
the viral pathogen will be in contact with the host in order to 
carry out the prophylactic immunobiotic treatment. This option 
could be used for example during a school or work outbreak 
in which cases of respiratory infections occur and it is desired 
to prevent or reduce the severity of infections in asymptomatic 
individuals. For an intervention of these characteristics, it would 
be also important to determine the exact time after the contact 
with the virus in which it is possible to administer immunobi-
otics to achieve the beneficial effect. In a recent study, Percopo 
et al. (51) have defined this as “the window of opportunity.” The 
work evaluated the effect of the nasal administration of live or 
inactivated L. plantarum NCIMB 8826 in a mice model of severe 
respiratory infection with the pneumonia virus of mice (PVM) 
and found that immunobiotic treatment promoted full survival 
from acute PVM infection when administered within 1 day after 
virus challenge (51). Similar studies would be of value in IFV 
infection models.
Another point of interest is related to the duration of the 
improvement of respiratory defenses after the last immunobiotic 
administration. Our studies have showed that the immunomod-
ulatory effect of some nasally administered immunobiotics 
persisted for at least 15 days (Villena et al., unpublished results). 
Other studies have also reported short-term protection after 
nasal treatment with different immunobiotic strains (43). 
Interestingly, Garcia-Crespo et  al. (52) found that adult mice 
primed nasally with L. plantarum NCIMB 8826 or Lactobacillus 
reuteri F275 were completely protected against lethal PVM 
infection and that protection persisted for at least 5 months after 
the initial priming. These findings open an interesting challenge 
in the study of immunobiotics to improve the defenses against 
IFV, since it would be very useful to establish the duration of 
the protective effect for each strain and treatment, since in the 
majority of cases these long-term studies were not taken into 
account.
IFV infections often result in mild to moderate lung infec-
tion; however, life-threatening disease can occur. It has been 
demonstrated that the most severe disease outcomes are associ-
ated with secondary bacterial pneumonia caused primarily by 
Staphylococcus aureus or Streptococcus pneumoniae (53). Taking 
into account the high incidence of viral infections and the 
frequency of associated secondary bacterial infections which 
contribute to aggravate the health status of the host and reduce 
its chance of recovery, various approaches for preventing and 
treating influenza and secondary bacterial pneumonia are been 
investigated. A wide range of antibiotics and anti-inflammatory 
drugs has been tested in mice [reviewed in Ref. (54)]. It would 
be of interest to evaluate the potential beneficial effect of immu-
nobiotics on these circumstances. In this regard, preliminary 
studies from our laboratory showed that nasally administered 
L. rhamnosus CRL1505 is able to improve survival, reduce 
FigURe 3 | Activation of the immuno-coagulative response by influenza virus in the respiratory mucosa. Beneficial effects of immunobiotics 
administration on the immuno-coagulative response triggered by toll-like receptor 3 or Influenza Virus in the respiratory mucosa.
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bacterial cell counts in lung and blood, and limit lung inflam-
matory damage caused by S. pneumoniae infection in mice 
produced after the infection with IFV or respiratory syncytial 
virus (RSV) (Villena et al., unpublished results). These results 
opened an interesting topic for future investigations.
Finally, it would be also of interest to investigate whether 
immunobiotic treatments may influence other physiological 
systems involved in the defenses against viral respiratory infec-
tions such as the coagulation system. Our group has made some 
progress in this regard, as mentioned below.
ReSPiRATORY iMMUNe-COAgULATive 
ReSPONSe AND iFv
Coagulation is an extremely ordered process that involves the 
interaction of three key components: endothelial cells (ECs), 
platelets, and coagulation factors. Tissue injury that activates 
ECs typically initiates coagulation that is characterized by the 
binding of platelets to activated ECs and the formation of the 
platelet plug. Almost simultaneously, tissue factor (TF) released 
by ECs result in factor X activation, which induces thrombin 
and the generation of fibrin strands to strengthen the platelet 
plug leading to a stable platelet–fibrin clot. All these processes 
are tightly regulated by anticoagulant and fibrinolytic mecha-
nisms to avoid thrombotic and/or haemorrhagic complications. 
A key role has been attributed to ECs in the temporal and special 
regulation of coagulation activation. Resting ECs avoid the 
inappropriate plug formation by controlling platelet adhesion 
and activation and generating several anticoagulant factors 
providing a non-thrombogenic barrier (55, 56). Once activated 
or injured, ECs expose collagen to blood, increase platelet 
binding and aggregation, reduce the expression physiological 
anticoagulant factors, increase the expression of TF and von 
willebrand factor, and suppress the fibrinolytic activity (57, 58). 
All these changes in the hemostatic system facilitate thrombosis 
in the infected or inflammated tissue.
Both hemorrhagic and thrombotic complications have been 
described during IFV infection. Influenza is able to cause pulmo-
nary hemorrhage and edema related to coagulopathy or induce 
uncontrolled thrombosis through an over-activated coagulation 
(Figure 3) (55, 58). Animal models have helped to explain the 
mechanisms by which IFV infection activates coagulation and key 
role has been attributed to TF. It was described that IFV activates 
coagulation by enhancing TF production, thrombin generation 
and fibrin deposition in C57BL/6 mice (59). In a mice model 
of IFV infection, it was recently shown that wild-type animals 
increased lung TF expression and activation of coagulation but 
presented alveolar hemorrhage (60). Moreover, selective deletion 
of TF in epithelial cells from lung significantly reduced TF expres-
sion after IFV infection and had higher alveolar hemorrhage and 
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reduced survival than controls. On the contrary, deficiency of 
TF in either respiratory myeloid cells or ECs did not enhanced 
alveolar hemorrhage or modified survival of IFV-infected mice 
(60). These results indicate that an appropriate modulation in the 
production of TF in the lung during IFV infection is necessary to 
maintain tissue hemostasis avoiding hemorrhage and excessive 
fibrin deposition. Production of TF by lung epithelial cells will be 
required to maintain alveolar hemostasis during IFV infection, 
while excessive release of TF by macrophages and ECs would 
contribute to pathology and lung tissue injury (59, 60).
It is considered that ECs may play an important role in the 
pathogenesis of IFV. Influenza infection is able to induce alveolar 
edema and pulmonary hemorrhage through the alteration of ECs 
via several mechanisms, including direct damage and loss of tight 
junctions and apoptosis (61). In addition, recognition of damage-
associated molecular patterns such as HMGB1 or oxidized 
phospholipids through TLR4 activates ECs to drive lung injury 
(62). Direct stimulation of TLR3 by viral RNA also results in the 
upregulation of TF and the downregulation of thrombomodulin 
(TM) in ECs (63). At the same time, the inflammatory activa-
tion of ECs leads to the activation of the coagulation cascade. 
Inflammation caused by IFV infection increases various proin-
flammatory cytokines such as TNF-α, IL-1β, and IL-6 that induce 
the secretion of TF by ECs and monocytes (58). In addition to 
their roles in coagulation, activated proteins such as thrombin, 
FXa, and FVIIa also enhance the inflammatory response. The 
inflammatory potentiating abilities of coagulation factors are 
mediated through their activation of protease-activated recep-
tors (PARs) that are expressed in platelets, ECs, macrophages, 
and respiratory epithelial cells (58). The TF/thrombin/PAR-1 
pathway has been associated to the promotion of a deleterious 
innate inflammatory response to IFV infection in mice (64, 65).
Therefore, both the hyper-inflammatory response and the 
aberrant activation of coagulation, which are potentiated with 
each other, are involved in severe influenza pneumonia and are 
key events that have to be controlled in order to reach a favorable 
resolution of the infectious process.
BeNeFiCiAL eFFeCTS OF 
iMMUNOBiOTiCS iN iFv iMMUNe-
COAgULATive ReSPONSe
Considering the importance of the coagulative response in the 
outcome of influenza infection and the ability of immunobiotics 
to beneficially influence the immune response to this respira-
tory pathogen, we wonder whether some immunobiotic strains 
would be able to beneficially modulate the immuno-coagulative 
response triggered by IFV. For this purpose, we performed chal-
lenge-infection experiments in mice and evaluated the influence 
of viable and non-viable immunobiotic L. rhamnosus CRL1505 
strain on the respiratory immuno-coagulative response induced 
by IFV (41, 42).
Our data demonstrated that oral administration of L. rham­
nosus CRL1505 to mice significantly reduced lung viral titers and 
tissue damage after the challenge with IFV (41). We later explored 
the capacity of nasally administered L. rhamnosus CRL1505, alive 
or heat killed, to reduce the influenza burden of disease (42). 
Those treatments induced a significant decrease in IFV titers 
in lungs, lessened pulmonary damage, and increased survival. 
Interestingly, a similar effect was achieved with the nasal admin-
istration of viable and non-viable CRL1505 strain. Moreover, the 
nasal route was more efficient than the oral administration to 
protect mice against IFV infection (41, 42). The protective effect 
achieved by the immunobiotic strain was related to its ability to 
modulate the respiratory antiviral immune response, particularly 
to its capacity to improve the levels of IFN-γ and IFN-β in the 
respiratory tract (Figure 2). Type I IFNs trigger the activation of 
the JAK-STAT pathway and increase the expression of antiviral 
genes. In addition, IFN-γ is produced by immune cells, especially 
Th1 cells, and it further improves antiviral immune response by 
inducing activation of NK cells and macrophages. Therefore, 
the modulation of type I IFNs and IFN-γ would be responsible 
of the reduction of viral loads in IFV-infected mice previously 
treated with the CRL1505 strain, similarly to other immunobiotic 
strains as mentioned before (Table 1). We demonstrated that the 
CRL1505 strain increased the levels of gut CD3+CD4+IFN-γ+ 
T cells, induce a mobilization of these lymphocytes into the lung 
and enhanced the respiratory production of IFN-γ and the activ-
ity of local antigen presenting cells (41, 66, 67). It was also noted 
that nasal administration was more effective than the oral route 
to increase pulmonary CD3+CD4+IFN-γ+ T cells (41, 42). The 
mechanism by which nasally administered viable or heat-killed 
L. rhamnosus CRL1505 improves IFN-γ+ T cells population is 
not clear. However, our studies support the possibility that the 
immunobiotic strain L. rhamnosus CRL1505 impact in the nasal-
associated lymphoid tissue or bronchial-associated lymphoid 
tissue producing an innate imprinting in antigen presenting 
cells that contribute to the enhanced number and activity of 
CD3+CD4+IFN-γ+ T cells.
Our studies also showed that immunobiotic treatments were 
able to beneficially modulate the activation of coagulation dur-
ing respiratory viral infection, an effect that was not reported 
before (41, 42). Then, our studies were the first in demonstrating 
a beneficial modulation of the immune-coagulative response 
during respiratory TRL3 activation and IFV infection induced 
by immunobiotic microorganisms (Figure 3).
Although IFV is an ssRNA virus, it generates dsRNA replication 
intermediates that activate TLR3 and contribute to the initiation 
of the antiviral respiratory immune response. In fact, IFV trig-
gers type I IFN secretion through TLR3 recognition in immune 
(myeloid DCs or macrophages) and non-immune (fibroblasts or 
pneumocytes) cells (68). Challenge-infection experiments with 
respiratory viruses in TLR3−/− mice showed that TLR3 does not 
modify the clearance of viral pathogens but it is relevant for the 
modulation of the lung inflammatory response (69, 70). It was 
showed that wild-type mice mount a robust inflammatory 
response in the lung after IFV infection and that this process is 
significantly diminished in TLR3−/− animals (70). TLR3−/− mice 
showed a longer survival when compared wild-type animals and 
this effect was associated with a reduction of inflammatory cells 
recruitment and lower levels of inflammatory factors in the res-
piratory tract. Other in vivo studies also demonstrated that TLR3 
activation by poly(I:C) enhanced proinflammatory cytokines and 
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TABLe 2 | effect of probiotics on influenza virus (iFv) infection in humans.
Strain viability Route Population studied effects Reference
Lactobacillus fermentum 
CECT5716
Viable Oral (capsule) Randomized, double-blinded, and 
placebo-controlled human clinical 
trial in adults
Coadjuvant capability for anti-IFV vaccine. Lower 
incidence of influenza-like illness during 5 months 
after vaccination 
Increased proportion of NK cells, higher induction 
of Th1 cytokines and augmented specific T-helper 
and T-cytotoxic lymphocytes. Increased antigen 
specific IgA
(83)
Lactobacillus casei 
DN-114 001
Viable Oral (fermented 
dairy drink 
Actimel®)
Randomized, multicentre, double-
blind, and controlled studies in 
elderly population over 70 years 
of age
Coadjuvant capability for anti-influenza vaccine. 
Improved IFV-specific antibody titers after 
vaccination
(84)
Lactobacillus GG Oral (capsule) Randomized, double-blind, and 
placebo-controlled pilot study in 
adults
Coadjuvant capability for anti-IFV vaccine. 
Increased protective titer 28 days after vaccination 
for the H3N2 strain
(85)
Lactobacillus plantarum 
L-137
Non-viable 
(heat killed)
Oral (capsule) Randomized, double-blind, and 
placebo-controlled pilot study in 
adults
Improved levels of interferon (IFN)-β before 
vaccination
(86)
Bifidobacterium animalis 
ssp. lactis BB-12w and 
Lactobacillus paracasei 
ssp. paracasei 431w
Viable Oral (capsule 
and acidified 
dairy drink)
Randomized, double-blind, 
placebo-controlled, and parallel-
group study in adults
Coadjuvant capability for anti-IFV vaccine. 
Improved vaccine-specific secretory IgA in saliva. 
Significant higher levels of vaccine-specific plasma 
IgG, IgG1, and IgG3
(87)
Lactobacillus rhamnosus 
strains GG and LC705
Viable Macrophage 
stimulation
Human primary macrophages Quantitative different IL-1β and type I IFN gene 
expression levels in macrophages. Diminished 
IFV replication and production of viral proteins in 
macrophages
(88)
Lactobacillus pentosus 
b240
Non-viable 
(heat killed)
Oral (tablet) Randomized, double-blind, and 
placebo-controlled trial in elderly 
population over 65 years of age
Significant reduction of the incidence rate of the 
common cold
(89)
L. paracasei MoLac-1 Non-viable 
(heat killed)
Oral (jelly) Randomized, double-blind, and 
placebo-controlled trial in elderly 
nursing home resident volunteers
Coadjuvant capability for anti-IFV vaccine. 
Improvement of hemagglutination inhibition titers 
against all different types of influenza antigens 
analyzed. Improvement in antibody titers against 
A/H3N2
(90)
L. rhamnosus GG Viable Oral 
(supplemented 
milk)
Randomized, double-blinded, and 
placebo-controlled in children of 
2–6 years of age
Probiotic intervention did not reduce significantly 
the occurrence of the examined respiratory 
viruses, but the children that received the GG 
strain had fewer days with respiratory symptoms
(91)
Lactobacillus brevis 
KB290
Viable Oral (fermented 
drink)
Open-label, parallel-group trial in 
children of 6–12 years of age
Reduced incidence of IFV infection in 
schoolchildren
(92)
L. rhamnosus GG Viable Oral (added to 
breast milk or 
formula)
Randomized, double-blind, and 
placebo-controlled trial in infants 
between the first and third days 
of life
Significant reduction in the incidence of viral 
respiratory tract infections
(93)
Lactococcus lactis ssp. 
lactis JCM5805
Viable Oral (fermented 
dairy drink)
Randomized, placebo-controlled, 
and double-blind trial in adults
Significant decrease in major symptoms of 
influenza-like illness. IFN-α elicited by A/H1N1 
on peripheral blood mononuclear cells prepared 
from volunteers tended to be higher, and IFN-
stimulated gene 15 was significantly higher
(94)
antiviral factors expression (71), altered vascular permeability 
(72), and incremented the levels of D-dimers indicating that 
coagulation and fibrinolysis were triggered. In line with these find-
ings, it was observed that the levels of D-dimers in TLR3−/− mice 
were significantly lower than in wild-type animals after poly(I:C) 
administration (63). In addition, by using siRNA technology it 
was demonstrated that TLR3 is a key receptor in the induction 
of the procoagulant state in ECs (63). Challenge of those cells 
with the TLR3 agonist poly(I:C) induced a decrease of TM and 
an enhancement of TF expression in a time- and dose-dependent 
manner. The results obtained in our own in  vivo experiments 
were in line with these preceding reports (41, 42). We observed 
that three daily doses of nasally administered poly(I:C) to BALB/c 
mice induced a marked enhancement of inflammatory cells 
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(neutrophils and macrophages) and proinflammatory mediators 
(IL-1β, TNF-α, IL-8, and IL-6) in the respiratory tract. Moreover, 
TLR3 activation also induced an increase in TF expression and 
thrombin–antithrombin complex (TATc) levels in the lung while 
it reduced TM expression. These inflammatory–coagulative 
modifications were accompanied by respiratory tissue alterations 
and impairment of lung function (41, 42).
Of interest, we demonstrated that orally (41) or nasally (42) 
administered immunobiotics before the challenge with poly(I:C) 
differentially modulated the inflammatory-coagulative response. 
L. rhamnosus CRL1505 was able to reduce and increase the expres-
sion of TF and TM, respectively, after the respiratory activation 
of TLR3. Thus, the CRL1505 strain significantly diminished 
coagulation activation in blood and in the respiratory tract after 
the nasal stimulation with poly(I:C).
We also evaluated pulmonary coagulation during IFV infection 
(41, 42). The respiratory virus induced activation of coagulation 
in the lungs of infected mice as demonstrated by the increased 
levels of respiratory TATc. These procoagulant changes were 
related to alterations in the expression of TM and TF in lungs. 
Our findings are in line with previous studies in humans and 
animal models of influenza infection demonstrating increased 
lung fibrin deposition and enhanced numbers of intravascular 
thrombi in the respiratory tract (59, 73, 74). We demonstrated 
that immunobiotic treatment is able to significantly diminish the 
activation of coagulation in IFV-challenged mice. In fact, lower 
levels of respiratory TATc and a reduced expression of TF was 
observed in L. rhamnosus CRL1505-treated mice infected with 
IFV when compared to controls (41, 42).
As mentioned before, IFV promote a procoagulant state 
directly through its capacity to infect ECs and monocytes 
stimulating the expression of TF (75, 76). In addition, IFV 
induce activation of coagulation indirectly by the enhancement 
of proinflammatory factors such as IL-6 (75, 76). Therefore, 
the ability of immunobiotics to modulate the IFV-triggered 
immune-coagulative response could be explained by their direct 
influence on viral replication related to the enhancement of the 
antiviral state in the respiratory mucosa, and indirectly through 
the modulation of the inflammatory response. Considering this 
last point, we performed experiments using anti-IL-10R blocking 
antibodies in order to evaluate the role of the regulation of the 
inflammatory response in the reduction of coagulation activa-
tion. Results showed that IL-10 is important for the regulation of 
coagulation induced by the immunobiotic L. rhamnosus CRL1505 
(41). Blocking of IL-10R abolished the capacity of the CRL1505 
strain to change the expression of TM and TF in the lungs. This 
was in line with our previous studies evaluating the ability of L. 
rhamnosus CRL1505 to confer protection against inflammatory 
damage induced by TLR3 activation or RSV infection, which 
showed that IL-10 is a key factor for the reduction of lung injury 
(67). Additionally, it was demonstrated that lethal disease caused 
by IFV infection is prevented by IL-10 administration through 
the reduction of lung immunopathology (77). Moreover, TF 
expression and procoagulant activity of macrophages and ECs 
are reduced by IL-10 (78, 79).
Therefore, we demonstrated that immunobiotic administra-
tion induce an early increase in the levels of TNF and IL-6 
in the respiratory tract after poly(I:C), RSV, or IFV challenge, 
while the levels of those proinflammatory factors are significantly 
reduced later during infection (41, 42, 67). The early increase of 
proinflammatory mediators and the augmented levels of IFN-γ 
explain the ability of L. rhamnosus CRL1505 to diminish viral 
replication while the improved production of IL-10 would lead 
to a beneficial modulation of the immune-coagulative response 
which results in a reduced severity of lung damage. It has been 
suggested that respiratory viral infections increase the risk of 
venous thromboembolism and ischemic heart disease through 
ECs perturbation, coagulation activation, reduction of antico-
agulant factors, and inhibition of fibrinolysis (80–82). Then, 
our studies suggest that immunobiotics could be an interesting 
alternative not only to reduce the incidence and/or severity of 
respiratory viral infections, but in addition to reduce the risk 
of atherothrombotic alterations associated to respiratory viral 
infections.
CONCLUSiON
Research from the last decade has clearly demonstrated that 
beneficial microorganisms are able to modulate respiratory tract 
immunity and promote the resolution and lessen the severity of 
respiratory infections caused by pathogens such as IFV. Studies 
in animal models have demonstrated that orally or nasally 
administered immunobiotics are able to improve protection 
against IFV by three main mechanisms. First, immunobiot-
ics increase the respiratory antiviral state by their capacity to 
improve levels of type I IFNs, the number and activity of antigen 
presenting cells, NK cells, CD4+IFN-γ+ T, and IgA+ B lympho-
cytes, as well as the levels of systemic and mucosal specific 
antibodies. Second, immunobiotics beneficially modulate the 
IFV-triggered respiratory inflammatory response by inducing 
changes in the levels and kinetics of proinflammatory factors 
and immunoregulatory cytokines such as IL-10 that allow the 
clearance of virus with a minimal inflammatory lung tissue 
damage. Finally, as demonstrated by our recent research works, 
immunobiotics modulate lung immune-coagulative response 
triggered by TLR3 activation or IFV infection, mainly by down-
regulating lung TF and restoring TM levels. Studies in animal 
models suggest that immunobiotics would influence principally 
the innate immune response, modulating in that way the early 
antiviral inflammatory response and the subsequent cellular and 
humoral immune responses. Therefore, immunobiotics would 
have mainly an adjuvant effect. However, the exact molecular 
mechanisms by which immunobiotics differentially modulate 
the innate antiviral immune response against IFV remain to be 
elucidated.
Additionally, a growing number of studies in humans have 
examined the effect of immunobiotics on the incidence and sever-
ity of IFV infection. Considering the impact of immunobiotics 
in the innate immune response clinical studies have evaluated 
principally their potential adjuvant effects on IFV vaccination 
(Table 2). Although mechanistic studies have not been addressed 
in depth, there is promising evidence for beneficial effects of 
immunobiotics on human respiratory health and resistance 
against IFV. These observations might be helpful to propose new 
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